ArticleBlood2018

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

Ronan T Swords et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.